Real-world clinical outcomes of Trastuzumab Deruxtecan in HER2-expressing ovarian and endometrial Cancer

By afschroeder • August 21, 2026

Silverstein J, Alomaja O, Chatram D, Hajiabbasi M, Shachar E, Tseng CH, Thaker S, Bardia A, Karlan B, Hendrickson AW, Konecny GE. Real-world clinical outcomes of Trastuzumab Deruxtecan in HER2-expressing ovarian and endometrial Cancer. Gynecol Oncol Rep. 2026 Aug 12;66:102183. doi: 10.1016/j.gore.2026.102183. PMID: 42621866; PMCID: PMC13487597.

Tags: Antibody-drug conjugates, DOM STAT, Endometrial cancer, Fellow, General Internal Medicine, Hematology/Oncology, Hospitalist, ovarian cancer, Publications, real-world outcomes, trastuzumab deruxtecan

Interdisciplinary Weight Management in a Safety-Net Health System: A Pilot Implementation Study

DeCan C, Thure K, Pedley N, Cervantes B, Camargo O, Fing Castro K, Cabral J, Gallardo M, Rodriguez Reyes D, Perez A, Young S, Nafisi[...]

Mobile point-of-care testing to improve access to care for people experiencing homelessness and diabetes in Los Angeles

Berger-Cahn T, Shannon EM, Zunner-Keating B, Weaver C, Lee J, Takada S, Lilley CM, Metushi IG, Garner OB. Mobile point-of-care testing to improve access to[...]

Susan Ettner, PhD and Dennis J. Slamon, MD, PhD Elected to the National Academy of Medicine

The UCLA Department of Medicine (DoM) is pleased to congratulate Susan Ettner, PhD and Dennis Slamon, MD, PhD, on their election to the National Academy[...]